PRAX Director Granted 10,520 Options at $44.04 鈥� Form 4 Insight

Q: What insider activity did PRAX report on 26-Jun-2025?

Director William D. Young was granted a stock option for 10,520 shares at an exercise price of $44.04.

Q: Does the filing show any PRAX common stock sales or purchases?

No. The Form 4 reflects only an option grant; no common shares were bought or sold.

Q: When do the PRAX options granted to William D. Young vest?

They vest in twelve equal monthly installments over one year starting 26-Jun-2025.

Q: What is the expiration date of the newly granted PRAX options?

The options expire on 26-Jun-2035.

Q: How many derivative securities does the director own after this transaction?

Mr. Young now beneficially owns 10,520 derivative securities tied to PRAX common stock.

[Form 4] Praxis Precision Medicines, Inc. Insider Trading Activity

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Praxis Precision Medicines (PRAX) 鈥� Form 4 Insider Activity

Director William D. Young disclosed the grant of a stock option for 10,520 common shares on 26-Jun-2025 at an exercise price of $44.04. The option vests in twelve equal monthly installments over one year, beginning on the grant date, and expires on 26-Jun-2035. No open-market purchases or sales of common stock were reported. Following the transaction, Mr. Young beneficially owns 10,520 derivative securities linked to PRAX common shares. The filing was executed on 27-Jun-2025.

Positive

Director engagement: Award of 10,520 stock options indicates continued participation and incentive alignment of board member William D. Young.

Negative

Potential dilution: If exercised, the option grant would add 10,520 shares to the outstanding count, though the impact is likely immaterial.

Insights

TL;DR: Routine option grant; aligns director incentives, negligible immediate share impact.

The Form 4 shows a single derivative transaction: Director William D. Young received an option for 10,520 shares at $44.04, expiring in 2035 and vesting monthly over one year. There were no sales or direct share acquisitions. Such grants are customary board compensation and do not alter cash flows or near-term ownership structure. Dilution risk is minimal unless options are exercised; even then, the amount is immaterial relative to PRAX鈥檚 total shares outstanding. Overall, the filing is neutral for valuation but signals continued director engagement.

06/27/2025 - 04:55 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

YOUNG WILLIAM D

(Last)

(First)

(Middle)

C/O PRAXIS PRECISION MEDICINES, INC.

99 HIGH STREET, 30TH FLOOR

(Street)

BOSTON

02110

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Praxis Precision Medicines, Inc. [ PRAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$44.04	06/26/2025		A		10,520		⁽¹⁾	06/26/2035	Common Stock	10,520	$0	10,520	D

Explanation of Responses:

1. The shares subject to this option shall vest in twelve (12) equal monthly installments over one (1) year commencing on June 26, 2025.

Remarks:

	/s/ Alex Nemiroff, as Attorney-in-Fact	06/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What insider activity did PRAX report on 26-Jun-2025?

Director William D. Young was granted a stock option for 10,520 shares at an exercise price of $44.04.

Does the filing show any PRAX common stock sales or purchases?

No. The Form 4 reflects only an option grant; no common shares were bought or sold.

When do the PRAX options granted to William D. Young vest?

They vest in twelve equal monthly installments over one year starting 26-Jun-2025.

What is the expiration date of the newly granted PRAX options?

The options expire on 26-Jun-2035.

How many derivative securities does the director own after this transaction?

Mr. Young now beneficially owns 10,520 derivative securities tied to PRAX common stock.

AG真人官方

[Form 4] Praxis Precision Medicines, Inc. Insider Trading Activity

Insights

FAQ

What insider activity did PRAX report on 26-Jun-2025?

Does the filing show any PRAX common stock sales or purchases?

When do the PRAX options granted to William D. Young vest?

What is the expiration date of the newly granted PRAX options?

How many derivative securities does the director own after this transaction?

NASDAQ:PRAX

PRAX Rankings

PRAX Latest News

PRAX Latest SEC Filings

PRAX Stock Data

AG真人官方

Trending News

[Form 4] Praxis Precision Medicines, Inc. Insider Trading Activity

Insights

Securities Analyst neutral

FAQ

What insider activity did PRAX report on 26-Jun-2025?

Does the filing show any PRAX common stock sales or purchases?

When do the PRAX options granted to William D. Young vest?

What is the expiration date of the newly granted PRAX options?

How many derivative securities does the director own after this transaction?

NASDAQ:PRAX

PRAX Rankings

PRAX Latest News

PRAX Latest SEC Filings

PRAX Stock Data